Key takeaway: The investor presentation from Vijaya Diagnostic Centre Limited, dated August 6, 2026, outlines the company's financial results for the quarter ending June 30, 2026. Management reported a revenue from operations of INR 2,310 million, reflecting a year-on-year growth of approximately 22.8%. The EBITDA was INR 985 million with a margin of 42.7%, while the profit after tax (PAT) stood at INR 531 million, representing a PAT margin of 23.0%. The presentation highlighted the successful expansion of the company's network, including the commissioning of new hub and spoke centers in Hyderabad, Pune, and Bengaluru. Management emphasized the growth in wellness testing driven by increased awareness and lifestyle changes. The company plans to continue its expansion strategy, aiming to add multiple new centers in the coming year. The document also included a disclaimer regarding forward-looking statements and emphasized the importance of not relying solely on the presentation for investment decisions.

Key takeaway: During the earnings conference call held on May 8, 2026, management of Vijaya Diagnostic Centre Limited reported significant achievements over the past five years, including doubling the number of centers from 81 to 162 and expanding operations across six states. The company achieved a revenue CAGR of 17%, surpassing its guidance of 15%, with FY'26 revenues exceeding INR 800 crores. Q4 FY'26 saw a year-on-year revenue growth of approximately 26.5%, driven by strong performance in both pathology and radiology segments. Management highlighted plans for further expansion, including the commissioning of new hubs and spokes, and the introduction of advanced genomic testing. The EBITDA margin improved to 43.5%, reflecting operational efficiencies and successful new center breakeven. Management expressed confidence in maintaining growth momentum and creating long-term stakeholder value.

Key takeaway: The investor presentation from Vijaya Diagnostic Centre Limited, dated May 7, 2026, outlines the financial results for the quarter and year ended March 31, 2026. The presentation highlights a revenue from operations of INR 2,194 million for Q4 FY26, with an EBITDA of INR 955 million, reflecting a margin of 43.5%. For FY26, total revenue reached INR 8,142 million, with a PAT of INR 1,730 million and a margin of 21.2%. Management noted a 16.5% CAGR in revenues since listing, exceeding their long-term guidance. The company reported strong growth in both pathology and radiology segments, with plans to expand further by adding 4-5 hubs and 10-12 spokes in FY27. The presentation also emphasized the successful integration of technology and AI in operations, enhancing diagnostic capabilities and customer experience. Management expressed confidence in the ongoing expansion strategy and its positive outcomes.

Key takeaway: During the earnings conference call held on February 13, 2026, management reported that Vijaya Diagnostic Centre achieved its highest quarterly revenue of approximately INR 205 crores for Q3 FY26, reflecting a year-on-year growth of 21.4%. This growth was supported by a nearly 15% increase in test volumes. Management highlighted the successful ramp-up of new hubs, with two new centers in West Bengal achieving breakeven ahead of schedule. The company emphasized its integrated business model's resilience, with balanced growth across radiology and pathology segments. EBITDA for the quarter was reported at INR 86 crores, marking a 28.2% increase year-on-year, while profit after tax stood at INR 43 crores, reflecting a growth of 22.3%. Management also discussed ongoing investments in technology and talent to support future growth and indicated a focus on stabilizing newly launched hubs and expanding their network further.

Key takeaway: On February 13, 2026, Vijaya Diagnostic Centre Limited submitted an investor presentation detailing its financial results for the third quarter and nine months ended December 31, 2025. The presentation highlighted a revenue from operations of INR 2,052 million for Q3 FY26, reflecting a year-on-year growth of 21.4%. The EBITDA for the same period was reported at INR 861 million, with an EBITDA margin of 41.9%. The company noted a total footfall of 1.17 million and performed 4.22 million tests during the quarter. Management, represented by MD & CEO Ms. Suprita Reddy, commented on the successful expansion of their network, including new hub centers in West Bengal and Andhra Pradesh, and emphasized the importance of stabilizing these new hubs while continuing to invest in technology and customer experience. The presentation also included a strategic overview of the company's growth plans and recent leadership additions.